David Einhorn - Greenlight Capital
EDGAR CIK 1489933 ↗ · Waiting · typical filing lag 45 days · EDGAR name DME Capital Management, LP (Greenlight Capital, David Einhorn); Greenlight Capital Inc (1079114) last 13F 2024-02-14
| Security | Weight | Δ wt | Price* | Shares | Δ shares | Value | Action | |
|---|---|---|---|---|---|---|---|---|
| 1 | GRBK GREEN BRICK PARTNERS INC | 29.31% | +0.4% | $57 | 10.47M | +0.0% | $599M | Held |
| 2 | — CONSOL ENERGY INC NEW | 8.19% | +1.9% | $102 | 1.64M | +0.0% | $167M | Held |
| 3 | BHF BRIGHTHOUSE FINL INC | 6.30% | -0.8% | $43 | 2.97M | -1.6% | $129M | Trimmed |
| 4 | HPQ HP INC | 5.78% | +3.5% | $35 | 3.37M | +108.7% | $118M | Added |
| 5 | KD KYNDRYL HLDGS INC | 5.71% | -0.9% | $26 | 4.44M | -32.8% | $117M | Trimmed |
| 6 | PENN PENN ENTERTAINMENT INC | 4.82% | +1.0% | $19 | 5.10M | +11.9% | $98.62M | Added |
| 7 | ODP1 THE ODP CORP | 4.27% | +0.1% | $39 | 2.22M | +29.9% | $87.28M | Added |
| 8 | ALITEUR ALIGHT INC | 4.00% | -1.2% | $7 | 11.07M | -3.9% | $81.73M | Trimmed |
| 9 | THC TENET HEALTHCARE CORP | 3.89% | -0.4% | $133 | 598K | -32.9% | $79.51M | Trimmed |
| 10 | VTRS VIATRIS INC | 3.85% | +1.4% | $11 | 7.40M | +63.8% | $78.66M | Added |
| 11 | TECK TECK RESOURCES LTD | 2.55% | -0.7% | $48 | 1.09M | -30.0% | $52.05M | Trimmed |
| 12 | — ROIVANT SCIENCES LTD | 2.49% | +0.5% | $11 | 4.81M | +14.8% | $50.85M | Added |
| 13 | — DHT HOLDINGS INC | 2.28% | +0.2% | $12 | 4.02M | +0.0% | $46.56M | Held |
| 14 | GLD SPDR GOLD TR | 2.13% | -0.2% | $215 | 202K | -18.0% | $43.50M | Trimmed |
| 15 | GPK GRAPHIC PACKAGING HLDG CO | 1.79% | -0.6% | $26 | 1.40M | -22.3% | $36.59M | Trimmed |
| 16 | — LIBERTY GLOBAL LTD | 1.74% | +0.2% | $17 | 2.04M | +0.0% | $35.58M | Held |
| 17 | — LIVANOVA PLC | 1.73% | -1.7% | $55 | 644K | -51.7% | $35.32M | Trimmed |
| 18 | — SEADRILL 2021 LTD | 1.43% | +0.1% | $52 | 569K | +0.0% | $29.32M | Held |
| 19 | PTON PELOTON INTERACTIVE INC | 1.12% | +1.1% | $3 | 6.79M | new | $22.95M | New |
| 20 | — CAPRI HOLDINGS LIMITED | 1.11% | +1.1% | $33 | 685K | new | $22.65M | New |
| 21 | — WEATHERFORD INTL PLC | 1.06% | -0.6% | $122 | 177K | -44.1% | $21.72M | Trimmed |
| 22 | PPA INVESCO EXCHANGE TRADED FD T | 0.92% | +0.1% | $103 | 183K | +0.0% | $18.75M | Held |
| 23 | XAR SPDR SER TR | 0.87% | +0.1% | $140 | 128K | +0.0% | $17.86M | Held |
| 24 | PPLI IAC INC | 0.67% | +0.7% | $47 | 291K | new | $13.65M | New |
| 25 | COYA COYA THERAPEUTICS INC | 0.38% | -0.2% | $6 | 1.27M | +0.0% | $7.72M | Held |
| 26 | LKFT GALAPAGOS NV | 0.28% | +0.0% | $25 | 235K | +46.9% | $5.82M | Added |
| 27 | TEVAN TEVA PHARMACEUTICAL INDS LTD | 0.26% | +0.0% | $16 | 325K | +0.0% | $5.28M | Held |
| 28 | GPRO GOPRO INC | 0.20% | -0.1% | $1 | 2.82M | +0.0% | $4.01M | Held |
| 29 | GDX VANECK ETF TRUST | 0.18% | +0.0% | $34 | 111K | +0.0% | $3.78M | Held |
| 30 | SHC SOTERA HEALTH CO | 0.17% | +0.0% | $12 | 300K | +0.0% | $3.56M | Held |
| 31 | OIH VANECK ETF TRUST | 0.17% | +0.0% | $316 | 11K | +0.0% | $3.55M | Held |
| 32 | FCG FIRST TR EXCHANGE-TRADED FD | 0.09% | +0.0% | $26 | 71K | +0.0% | $1.86M | Held |
| 33 | — DANIMER SCIENTIFIC INC | 0.08% | -0.1% | $1 | 2.73M | +0.0% | $1.65M | Held |
| 34 | PDBC INVESCO ACTVELY MNGD ETC FD | 0.08% | +0.0% | $14 | 117K | +0.0% | $1.65M | Held |
| 35 | — TALIS BIOMEDICAL CORP | 0.06% | +0.0% | $9 | 149K | +0.0% | $1.29M | Held |
| 36 | GANX GAIN THERAPEUTICS INC | 0.04% | -0.1% | $1 | 566K | +0.0% | $725K | Held |
| 37 | NUVB NUVATION BIO INC | 0.00% | -0.0% | $3 | 35K | +0.0% | $102K | Held |
| 38 | NUVB/WS NUVATION BIO INC | 0.00% | -0.0% | $0 | 100K | +0.0% | $16.00K | Held |
| 39 | — KATAPULT HOLDINGS INC | 0.00% | -0.0% | $0 | 262K | +0.0% | $3.02K | Held |
| 40 | FCNCA FIRST CTZNS BANCSHARES INC N | 0.00% | -1.9% | — | 0 | 25K → 0 | $0 | Exited |
| 41 | — AERCAP HOLDINGS NV | 0.00% | -1.3% | — | 0 | 319K → 0 | $0 | Exited |
| 42 | NPWR NET POWER INC | 0.00% | -1.0% | — | 0 | 1.96M → 0 | $0 | Exited |
| 43 | J4D KENVUE INC | 0.00% | -0.7% | — | 0 | 708K → 0 | $0 | Exited |
| 44 | — CLARIVATE PLC | 0.00% | -0.1% | — | 0 | 280K → 0 | $0 | Exited |
| 45 | — NEUBASE THERAPEUTICS INC | 0.00% | -0.0% | — | 0 | 136K → 0 | $0 | Exited |
* Price = reported value ÷ shares at quarter end (13F does not disclose cost basis). Δ wt = this position's share of the reported portfolio versus the prior quarter. Options are shown separately when filed.
| Quarter | Period end | Reported value | Positions | Largest | New | Exited | Filed | Lag |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.91B | 46 | 19.4% | 7 | 6 | 14 Aug 2026 ET | 45 |
| Q1 2026 | 2026-03-31 | $3.19B | 45 | 19.1% | 11 | 7 | 15 May 2026 ET | 45 |
| Q4 2025 | 2025-12-31 | $2.85B | 41 | 20.8% | 8 | 4 | 17 Feb 2026 ET | 48 |
| Q3 2025 | 2025-09-30 | $2.54B | 37 | 27.5% | 4 | 1 | 14 Nov 2025 ET | 45 |
| Q2 2025 | 2025-06-30 | $2.33B | 34 | 25.6% | 4 | 3 | 14 Aug 2025 ET | 45 |
| Q1 2025 | 2025-03-31 | $1.97B | 33 | 28.0% | 2 | 5 | 15 May 2025 ET | 45 |
| Q4 2024 | 2024-12-31 | $1.94B | 36 | 27.5% | 5 | 7 | 14 Feb 2025 ET | 45 |
| Q3 2024 | 2024-09-30 | $2.40B | 38 | 32.9% | 1 | 2 | 14 Nov 2024 ET | 45 |
| Q2 2024 | 2024-06-30 | $2.04B | 39 | 29.3% | 3 | 6 | 14 Aug 2024 ET | 45 |
| Q1 2024 | 2024-03-31 | $2.18B | 42 | 28.9% | — | — | 15 May 2024 ET | 45 |
| Quarter | Book | S&P 500 | Excess | Coverage | Best call |
|---|---|---|---|---|---|
| Q2 2026 | -8.3% | -4.1% | -4.1% | 85% | ACHC +24.7% |
| Q1 2026 | +5.5% | +0.9% | +4.5% | 86% | VSXY +119.9% |
| Q4 2025 | +2.0% | +9.6% | -7.6% | 80% | CNC +81.4% |
| Q3 2025 | +5.2% | +11.7% | -6.5% | 81% | VSXY +183.2% |
| Q2 2025 | +4.5% | +16.7% | -12.2% | 78% | CNC +177.8% |
| Q1 2025 | +4.0% | +27.8% | -23.8% | 78% | VTRS +150.4% |
| Q4 2024 | -5.6% | +24.1% | -29.7% | 71% | VTRS +106.4% |
| Q3 2024 | -4.4% | +28.0% | -32.4% | 71% | VTRS +78.2% |
| Q2 2024 | +6.1% | +40.1% | -34.0% | 71% | VTRS +99.3% |
| Q1 2024 | +10.0% | +44.3% | -34.2% | 70% | THC +118.7% |
Simulation: at each filing date, buy the manager's ten largest reported common-stock positions in equal weight; hold until the next filing. Prices are split- and dividend-adjusted closes. It ignores the 45-day disclosure lag's cost to a real copycat beyond the filing-date entry, taxes, fees and liquidity. It is a reading aid, not a backtest of the manager's fund.